We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Polarean Imaging Plc | POLX | London | Ordinary Share |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
3.85 | 3.65 | 3.85 | 3.75 | 3.85 |
Industry Sector |
---|
PHARMACEUTICALS & BIOTECHNOLOGY |
Top Posts |
---|
Posted at 16/5/2024 07:23 by moontheloon From pirates last post its so clear the benefit of the tech on identifying lung deficiencies. Without radiation so able to re scan to see affect of medication instead of the historic mri at last choice due to radiation affects. This seems perfect. The world will catch on and investors. It's started. |
Posted at 14/5/2024 12:51 by pirates4 That was before Polarean was granted the FDA approval, since then Philips, VIDA diagnostic, and Oxford University have collaborated and children hospital In missouri has too. More collaborations once they attend the ats in USA, or we could see investors interested in the tech before that jmo. |
Posted at 13/5/2024 15:08 by goldbutler Moontheloon YOUR post 6686 re GEHealthcare, Prof Driehuis and Duke university is excellent news and is on the other chat board also.Really should be read by every investor and would be investor I hope the forthcoming RNS's are issued between 4 and 4.30 for the benefit of those shorting the share. Zak Mir on Sharetalk has referred to the shorting going on with Aim shares |
Posted at 10/5/2024 14:51 by pirates4 Investors see an opportunity here stoll buying g in thousands |
Posted at 10/5/2024 08:41 by john henry Boney what your not grasping is that 80% of the funding is secured from Cornerstone investors and Government grant.Who will take the remaining 20% Philips, Directors. Retail wont be involved unlike GDR which was 100% retail, hence the 54% discount. You have to look at each companies merits individually rather than tar them all with the same brush, something you seem incapable of doing. |
Posted at 10/5/2024 08:35 by john henry Imho the market /investors are visible see traction taking hold.Its taken 18 months but starting to generate revenues which will only grow from here. Remember its the razor blades that will generate the growth revenue. |
Posted at 10/5/2024 07:48 by john henry If the company has strong underpinning Fundamentals with Cornerstone investors then a placing can be done around 5-10% discount. Reference, Illika 5.1% as opposed to GDR 54%. |
Posted at 10/5/2024 07:13 by john henry Moontheloon fundamentals get stronger ever month however the elephant in the room is funding, get that sorted and the share price will move strongly north.Example GDR overnight, abiet the difference here is that POLX have large cornerstone investors, GDR is all retail., never good. |
Posted at 04/4/2024 12:31 by goldbutler The Board of Directors including Bracco representative director and Nukemsaid that 9 conversions were planned for 2 years wave 1 and wave 2 Wholly inadequate for the company survival funded by 27 million pounds and more from AIM investors On a monthly basis 28 people receive a very handsome pay cheque and the CEO cannot bring himself to refer to shareholders He never stops on Linkedin including references to a previous company So where is the investor presentaion for AIM INVESTORS for wave 1 and 2 Wave 1 Wave 2 Ohio Texas Missouri Iowa N.Carolina Kansas Virginia Illinois Wisconsin Where is the commercial strategy including partnerships for sales into UK and Europe and arab states where there is no shortage of cash and significant COPD problem. Why would any board of directors behave like this and for 18 months warn and advise of a cash raise and see the share price destruction. |
Posted at 29/2/2024 07:40 by john henry Strategic investors committed funding, funding from UK government.Additional few millions quid required from Investors. Im guessing the board will invest along with a few new Institutions. What price ? imho 5-10p |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions